PCSK9 and gout: In the current investigation, we employed a two-sample Mendelian Randomization analysis approach to explore the relationship between lipid-lowering agents (HMGCR inhibitors, PCSK9 inhibitors, and NPC1L1 inhibitors) and outcomes related to urate and gout.